During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.

NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.

Deal Snapshot: Vividion hopes Tavros’s functional and computational genomics technology will help it discover and validate novel targets in precision oncology therapy.

Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.